Metoprolol Orion

Metoprolol tartrate, the active ingredient in Metoprolol Orion, is a selective β1‑adrenergic receptor blocker presented as an oral tablet for systemic use. It is employed to lower high blood pressure, relieve angina pectoris, improve outcomes after myocardial infarction, support chronic heart failure management, and control certain cardiac arrhythmias.

GNH USA supplies Metoprolol Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Metoprolol Orion is a beta‑blocker indicated for several cardiovascular conditions.

Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. Post‑myocardial infarction: improves survival and reduces recurrence of ischemic events. Chronic heart failure: enhances left ventricular function and reduces hospitalization. Cardiac arrhythmias: controls heart rate in supraventricular tachyarrhythmias.

Metoprolol Orion may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Cold extremities (hands, feet) - Bradycardia (slow heart rate) - Gastrointestinal upset (nausea, abdominal discomfort) - Sleep disturbances or vivid dreams

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in asthmatic patients - Depression or mood changes - Exacerbation of heart failure - Allergic reactions (rash, angioedema)

When prescribing Metoprolol Orion, clinicians should consider several precautionary measures to ensure safe use.

Cardiovascular assessment: evaluate heart rate and blood pressure before initiation. Respiratory conditions: use cautiously in patients with asthma or chronic obstructive pulmonary disease. Diabetes monitoring: monitor blood glucose as β‑blockade may mask hypoglycemia symptoms. Concomitant drugs: review for potential interactions, especially with other rate‑controlling agents. Renal/hepatic impairment: dose adjustment may be required in severe dysfunction. Store at below 25°C: keep in the original container, protect from moisture and light.

Metoprolol Orion can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): risk of severe heart block. - Clonidine abrupt withdrawal: may cause rebound hypertension. - Insulin or oral hypoglycemics: mask hypoglycemia signs. - Potassium‑sparing diuretics: increase risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive effect. - NSAIDs: may reduce antihypertensive efficacy. - Antidepressants (SSRIs): may increase bradycardia risk.